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Abstract
Background and Aims: Stage II cancer of the tongue is mostly managed surgically both
locally and regionally. However, indications for postoperative radiotherapy and reconstructive
options vary between centers. This paper aims to describe differences in treatment in a
geographically homogenous cohort.
Methods: A retrospective comparison was made between two cohorts of clinical T2N0
tongue cancer from Finland and Sweden. The Finnish cohort included 75 patients and the
Swedish 54. All patients had curative intent of treatment and no previous head and neck
cancer. Data analyzed consisted of pathological stage, size and thickness of tumor, frequency
of reconstruction, radiotherapy delivered, and survival.
Results: The Finnish cohort included a higher proportion of patients managed with
reconstructive surgery (67%) than the Swedish cohort (0%), p<0.00001. More patients were
treated with postoperative radiotherapy (84%) in the Swedish cohort than in the Finnish
(54%), p<0,0002. The Finnish cohort had a higher level of survival and included more
frequent downstaging (cTNM to pTNM).
Conclusions and significance: Our data indicate a major difference in the management of
T2N0 oral tongue cancer. The optimal cut-off size and growth pattern of the tumor warranting
reconstruction should be further evaluated in a prospective manner considering both survival
and quality of life.
Introduction
Oral tongue squamous cell carcinoma (OTSCC) is one of the most common head and neck
cancers in the Nordic countries (Nordcan). There have been reports of an increasing incidence
trend among young adults [1] and the current age-adjusted incidence (/100 000) in Sweden
and Finland is 3,4 and 3,4 for women and 4,1 and 5,0 in men, respectively (Nordcan, 2016).
The survival has not changed in Sweden during the last decades [2] but in Finland an
improvement has been recently reported [3].
Early stage OTSCC is most often primarily managed surgically as a single-modality treatment
or combined with postoperative (chemo)radiotherapy, and there are a great number of
investigations addressing the treatment of the N0 neck [3-5]. An emerging alternative is the
use of sentinel node biopsy and subsequent treatment of the neck based on the biopsy result
[6-8]. Primary radiotherapy is used to a lesser extent, mainly in patients with significant
comorbidities and advanced age and has been associated with a decreased overall and disease-
specific survival. However, these data are retrieved from register data [9,10] and may be
hindered by selection bias.
The recommendations for the postoperative treatment of stage II disease are mainly based on
the histopathological assessment of the surgical specimen. The guidelines of the NCCN, the
Swedish Head and Neck Cancer Register (SweHNR), and the Finnish Head and Neck
Oncology Working Group recommend postoperative radiotherapy when adverse
histopathological features are present, when the margin is close/positive or when the neck is
positive. The SweHNR recommends PORT in T2 and larger lesions. These recommendations
can, however, be broadly interpreted when for example patient-specific criteria such as
comorbidities, preferences and age are addressed. Also, there is an obvious lack of
randomized controlled trials regarding functional and quality of life (QoL) results of various
reconstruction options in OTSCC patients. Therefore, scarce information exists regarding the
indications for the use of free tissue transfers in the reconstruction of the surgical defect. The
available data are most often single institution series and to our knowledge only one
comparison study has been published with survival as the major outcome [11]. Therefore, the
indications to reconstruct or not probably vary between centres and large variations may exist.
There are no clear guidelines regarding the reconstruction of a surgical tongue defect after
cancer resection. We aimed to compare the OTSCC management protocols in Sweden and
Finland due to the differing reconstructive approach for T2 OTSCC in these two Nordic
countries. Therefore, we performed a descriptive analysis of the treatment of stage II OTSCC
at the Karolinska University Hospital (Stockholm, Sweden) and at two university hospitals in
Finland (Helsinki and Oulu). Since the guidelines for delivering postoperative radiotherapy
differ we also aimed to investigate the clinical parameters governing the decision to
reconstruct the lesion and to offer postoperative radiotherapy.
Materials and methods
All patients treated for clinically stage II (TNM7) OTSCC at the Karolinska University
Hospital (Stockholm, Sweden; years 2008-2014 [5]) and at the Helsinki and Oulu University
Hospitals (Finland; years 2004-2014 [3]) were included. Only patients treated with a curative
intent for a first primary tumor in the head and neck region were included.
Clinical data on gender, age, tumor location, tumor thickness, histopathological assessment of
primary tumor, macro- or microscopic tumor or isolated tumor cells on histopathological
evaluation of the neck specimen, margin status, postoperative radiotherapy, presence of and
type of reconstruction, local recurrence or isolated regional recurrence were recorded.
Recurrence-free survival was analyzed as the time from diagnosis to recurrence. Overall
survival was analyzed as time from diagnosis to death of any cause. Disease-specific survival
was recorded as time from diagnosis to death caused by the disease. A second primary
resulted in censoring.
Kaplan-Meier curves were constructed to describe the different survival trends and a log-rank
test was performed to test for any difference(s). A stratified test for pT2N0 stages was also
performed. Categorical data were analyzed using either the Chi-square test or Fishers exact
test when appropriate. For continuous data, Student’s t-test was used.
Results
At the Karolinska University Hospital, there were 54 patients diagnosed with a cT2N0M0
OTSCC and 75 patients at the Helsinki and Oulu University Hospitals during the study period
(Table 1). The median age at diagnosis did not differ between the two cohorts (p=0,3).
Differences in depth of invasion between the two cohorts did not reach statistical difference
(p=0,8), but there was a significant difference in tumor diameter between the centers with a
larger diameter in the Stockholm patients (p=0,0006).
Significantly more patients were treated with postoperative radiotherapy in the Stockholm
cohort (84%) than in the Finnish (54%), p<0,0002. The patients in the Finnish series were
reconstructed more often than in Stockholm, 67% vs. 0% (p<0,00001). The most frequently
used flap type was the radial forearm free flap, which was used in 76% of the Finnish cases.
Neck dissections were performed in patients treated in Stockholm equally as often as in the
Finnish patients (p=0,888).
Regarding the pathological stage, a significantly higher proportion were down-staged after
pathological evaluation to stage I in Finland than in Stockholm (39% vs. 17%; p=0,0073).
Only two patients in the Finnish series and none in the Stockholm series were up-staged to
T3. The main reason for up-staging were due to N-site positivity: 44 % in Stockholm and 31
% in Finland (p=0,189). In Stockholm, 43% of the patients had the same pathological and
clinical staging compared with 34% in Finland (p=0,30).
Five-year overall survival was 57% in Stockholm and 73% in Finland, disease-specific
survival 65% and 89%, and recurrence-free survival 62% and 77%, respectively. Regarding
the stratified test for pathological stage II patients the survival benefitted the Finnish cohort
when disease-specific and overall survival were analyzed (Figures 1 and 2). When the data
were analyzed for recurrence free-survival, no significant differences were seen between the
curves (Figure 3).
Discussion
This study reveals a difference in the treatment approach of early stage tongue cancer
(cT2N0M0) within a geographically and culturally homogeneous population in the Nordic
countries. The two major differences concerned the indications for postoperative radiotherapy
and reconstruction of the surgical defect. Variations in the management protocol may have
contributed to survival differences.
Administration of postoperative radiotherapy is based on pathological tumor stage, margins
and the histopathological evaluation of the specimen. Also, performance status and co-
morbidities of the patient are considered in the decision making for postoperative
radiotherapy. In this study, a significant difference was found in the use of postoperative
radiotherapy between the two countries. However, one must consider that the differences in
margin and histopathological assessment may explain these differences. For example, when
the decision to administer radiotherapy is based on the pathological stage it is noteworthy that
patients in the Finnish cohort were down-staged to a higher extent than those in the
Stockholm cohort. However, this statement allows for broad interpretation and one should
probably analyze differences prospectively between the different sites to assess eventual
differences in the postoperative treatment of these patients. Subramaniam et al. reviewed the
literature regarding the treatment of early stage tongue cancers and found that patients with
multiple adverse pathological features were more likely to benefit from radiotherapy than
patients with single adverse pathological features. However, this study was performed using
the 7th TNM classification and one of the adverse features was tumor thickness [12]. The
authors highlight the need for a re-evaluation of the topic using the latest TNM classification.
The decision to reconstruct an oral tongue defect should be based on either the probability of
achieving a greater tumor-free margin, hence reducing the risk of local recurrence, or
providing a better QoL for the patient after the treatment. The decision to reconstruct the
surgical defect or not was found to differ significantly between the two sites in the present
study. There is clearly a more conservative approach toward microvascular reconstruction in
Stockholm than in Finland. There seems to be a significant survival difference between the
studied sites i.e. Finland having a much higher overall, recurrence-free and disease-specific
survival. There is however, a slightly uneven distribution of pathological stages between these
sites i.e. the Finnish series having overall significantly lower stages than the one from
Stockholm. When stratifying for pT2N0 this survival difference remained except for
recurrence-free survival. The basis for this finding is unclear but it might reflect a similar
primary treatment effect in these cohorts, but a higher rate of successful salvage treatment in
the Finnish one.
One of the difficulties in analyzing oral tongue tumors is the mixing of tumor sites in the
analysis. Some authors report on tongue cancer specifically but there seems to be a mixture of
stages included. The data are most often collected retrospectively and the histopathological
aggressiveness is not considered. Also, regarding the surgical excision, there seems to be an
incomplete definition of the resection type performed. An effort to harmonize the used
technique and indications has been made by Ansarin et al. [13]. They described a definition
for tongue surgery and the indications upon which the surgical technique should be used. This
proposal may serve as a platform for more unified criteria to be used in the comparison
between studies.
One of the indications to reconstruct a tongue defect with a free flap could be the intention to
ensure adequate surgical margins whilst preserving deglutition function. The current
oncological literature is scarce regarding the comparison between outcome after oral tongue
reconstruction and non-reconstructive surgery. However, Lu et al. reported on the outcome
difference between these approaches in a series of 347 OTSCC patients [14]. Single
institutional data were grouped based on reconstructive approach. They found an increased
pathological free margin and a relative lower recurrence and good survival rates in those
patients who were reconstructed in comparison to those who were not. Although the data are
retrospective and selection bias cannot be ruled out, this is an important paper highlighting the
need for further investigations in this area. Also, the type of surgical resection included in the
analysis needs to be defined more thoroughly.
There are few studies addressing the possible benefit of microvascular reconstruction after
partial tongue resection. A prospective study from 1998 showed equal or better function in the
primary closure group than in the reconstructed group in comparable locus of resection [15].
This study is however 20 years old and the patient inclusion is even older and there has been a
great improvement in the available free-tissue transfer techniques since then. Ji et al. also
performed a retrospective analysis between reconstruction and non-reconstruction in a series
of 47 OTSCC patients evaluating speech, swallowing and tongue mobility 2-3 years after
surgery [11]. However, their series included patients from partial to total glossectomies. They
found a significantly better functional outcome for the non-reconstructed patients. These
results are in line with data published from some other centers investigating the role of oral
and oropharyngeal reconstruction [15,16]. When the resection is larger the literature is more
supportive towards reconstruction. Ji et al. reported in a series of patients with
hemiglossectomy or larger resections, a better tongue mobility, articulation, verbal
diadochokinesis and speech intelligibility for those patients who were reconstructed in
comparison to those who were not [11]. Canis et al. also found a superior QoL for patients
with a T3 tongue cancer treated with reconstruction in comparison to those who were not
reconstructed [17]. Both those studies are however retrospective in nature and may be
exposed to confounding factors. According to Sun et al. the tumor site and size and thus, also
the extent of tongue resection may be the key factors in determining the postoperative
articulation intelligibility in glossectomy patients [18]. Despite the fact that QoL
measurements include important parameters in head and neck oncology, there is still a
remarkable lack of consistency and uniformity of reporting of functional outcomes in the
literature [19]. This has been highlighted by Kansey et al. who described considerable
variation in the need for reconstruction and in the appropriate reconstructive techniques
among head and neck surgeons [20].
The retrospectively collected data in this study involves an inherent risk of bias. However, the
study is descriptive and not analytic and aims to describe the present differences in treatment
between two geographically and culturally homogenous areas. There is an indisputable
difference in the reconstructive protocol between these centers. This difference should be
further evaluated in a prospective setting to assess what stages and pattern of tumor growth
warrant reconstruction. More importantly, the differences should be evaluated based on
disease outcome and QoL measures.
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65 (24-97) 63 (22-89) p=0,3
Gender male/female
(%)




26 (12-40) 21 (3,5-49) p=0,0006
Invasion-median and
range
9 (2-19) 8,1 (1,5-30) p=0,8
Differentiation
low/mediate/high. (%)
13/27/14 (24/50/26) 22/36/9 (33/54/13) p=0,189
cTNM-T2N0M0 54 75


















pT1 12 38 p=0,0073
pT2 36 34 p=0,11
pN-stage
pN0 22 (56%) 42 (69%)
pN1 8 (21%) 10 (16%)
pN2 9 (23%) 9 (15%) p=0,1889
Treatment
Surgery-local (%) 49 (90%) 75 (100%) p=0,0053
+neckdissection (%) 39 (80%) 61 (81%) p=0,888
Reconstruction of
primary site (%)
0 (0%) 50 (67%) p<0,00001
Partial glossectomy 31 (63%) 39 (52%) p=0,229
Hemiglossectomy 18 (37%) 34 (45%) p=0,379
Subtotal glossectomy 0 2 (3%) p=0,321
Flaps
-ALT 0 8 (16%) NA
-RFA 0 38 (76%) NA
-lateral arm 0 2 (4%) NA
-pectoral 0 2 (4%) NA
Adjuvant radiotherapy
(%)
42 (86%) 41 (54%) p=0,0002
Adjuvant
chemoradiation (%)
9 (18%) 7 (9%) p=0,157
Only radiotherapy 5 0 NA
Only chemoradiation 2 0 NA
p=0.027
p=0.14
p=0.002
p=0.05
p=0.11
p=0.69
